SEC Form 4 · accession 0000886163-18-000152

LIGAND PHARMACEUTICALS INC · LGND

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Oct 12, 2018

Accepted (ET)

Oct 15, 2018 · 12:55 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000886163

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Oct 12, 2018	M	2,754	$89.75	A	45,310	D
Common Stock	Oct 12, 2018	M	2,329	$119.30	A	47,639	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F1	$89.75	Oct 12, 2018	M	2,754	D	—	Apr 24, 2025	Common Stock	2,754	0	D
Non-Qualified Stock Option (right to buy)^F2	$119.30	Oct 12, 2018	M	2,329	D	—	May 23, 2026	Common Stock	2,329	0	D

F1Acquired by a grant of the Board of Directors of the Company at their annual meeting on April 24, 2015. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
F2Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 23, 2016. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.